MPNPH: Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

• Sponsor: Odense University Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT02580903
• Collaborator: (none)
• Enrollment: 180
• Location: 1
• Duration (Months): 60
• Patients Per Site Per Month: 3

Study Details

Study Description

Brief Summary

This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis.

All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association.

All patients will be followed up for a total of five years to identify prognosis.

Condition or Disease	Intervention/Treatment	Phase
Myeloproliferative Disorders; Pulmonary Hypertension	Radiation: Radiology

Study Design

• Study Type: Observational
• Actual Enrollment: 180 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Pulmonary Hypertension in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms; an Observational Prospective Study
• Study Start Date: Feb 1, 2015
• Actual Primary Completion Date: Feb 1, 2018
• Actual Study Completion Date: Feb 1, 2020

Outcome Measures

Primary Outcome Measures

1. Prevalence of pulmonary hypertension at initial presentation and first echo [Initial recruitment]

Secondary Outcome Measures

1. Mortality [1 and 5 years]

2. Incidence of pulmonary hypertension while under follow-up [5 years]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Myeloproliferative Neoplasms (PV, ET, PMF according to WHO classification)

Exclusion Criteria:

• Pregnancy

• Lack of informed consent

• Age < 18 years

• Cognitive dysfunctions

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Odense University Hospital	Odense		Denmark	5000

Sponsors and Collaborators

• Odense University Hospital

Investigators

• Principal Investigator: Mette Brabrand, MD, Odense University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Mette Brabrand, Staff Specialist, Odense University Hospital
• ClinicalTrials.gov Identifier: NCT02580903
• Other Study ID Numbers: MPNPH
• First Posted: Oct 20, 2015
• Last Update Posted: Sep 16, 2020
• Last Verified: Sep 1, 2020

• Additional relevant MeSH terms: Neoplasms; Hypertension, Pulmonary; Hypertension; Myeloproliferative Disorders

Study Results

No Results Posted as of Sep 16, 2020